MedTrace Logo

Optimal Management of Rheumatoid Arthritis Patients Requiring Biologic Therapy

NCT01021735 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 302

Last updated 2015-05-29

No results posted yet for this study

Summary

That anti-TNF therapy and rituximab therapy are equally effective in treating patients with rheumatoid arthritis who meet the eligibility criteria for biologic therapy in the British Society for Rheumatology guidelines, and have not previously been exposed to biologic therapy.

Conditions

Interventions

DRUG

etanercept or adalimumab

etanercept 50mg/week by s/c injection adalimumab 40mg eow by s/c/ injection

DRUG

Rituximab

1g x2 by IV infusion repeated every 5 months or more

Sponsors & Collaborators

  • Arthritis Research UK

    collaborator OTHER

  • NHS Lothian

    collaborator OTHER_GOV

  • NHS Grampian

    collaborator OTHER_GOV

  • NHS Tayside

    collaborator OTHER_GOV

  • NHS Borders

    collaborator OTHER_GOV

  • NHS Fife

    collaborator OTHER_GOV

  • University of Glasgow

    lead OTHER

Principal Investigators

  • Duncan Porter, BM BCh · University of Glasgow

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2014-12-31
Completion
2015-04-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01021735 on ClinicalTrials.gov